Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.02 +2.1%	$18.16	$10.96 ▼ $34.84	$709.93M	2.19	1.03 million shs	1.78 million shs
PNTG The Pennant Group	$22.46 -3.4%	$27.79	$21.18 ▼ $37.13	$801.06M	1.51	239,482 shs	458,259 shs
VMD Viemed Healthcare	$6.50 +0.5%	$6.75	$6.14 ▼ $9.81	$255.72M	1.37	147,375 shs	208,672 shs
VRDN Viridian Therapeutics	$16.96 +1.0%	$14.80	$9.90 ▼ $27.20	$1.37B	0.39	1.13 million shs	393,670 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+7.05%	-36.31%	-33.04%	-28.25%	-29.52%
PNTG The Pennant Group	-0.81%	-8.32%	-16.34%	-7.96%	-14.37%
VMD Viemed Healthcare	-0.31%	-3.72%	-2.27%	-5.13%	-4.99%
VRDN Viridian Therapeutics	+1.63%	-2.04%	+14.06%	+22.02%	+16.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDNA CareDx	4.1759 of 5 stars	3.3	1.0	4.2	2.9	0.8	1.9
PNTG The Pennant Group	3.41 of 5 stars	3.3	3.0	0.0	2.2	2.5	1.9
VMD Viemed Healthcare	1.851 of 5 stars	0.0	2.0	0.0	3.2	3.3	1.3
VRDN Viridian Therapeutics	3.2131 of 5 stars	4.5	5.0	0.0	2.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.67	Moderate Buy	$29.33	125.29% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$33.80	50.49% Upside
VMD Viemed Healthcare	0.00	N/A	N/A	N/A
VRDN Viridian Therapeutics	2.90	Moderate Buy	$37.56	121.44% Upside

Current Analyst Ratings Breakdown

Latest VMD, VRDN, PNTG, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $26.00
7/16/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$32.00 ➝ $28.00
6/10/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00
6/3/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $31.00
5/20/2025	VRDN Viridian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/12/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$28.00 ➝ $32.00
5/7/2025	VRDN Viridian Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $27.00
5/7/2025	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $45.00
5/7/2025	VRDN Viridian Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$42.00 ➝ $38.00
5/7/2025	VRDN Viridian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $36.00
5/5/2025	CDNA CareDx	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$40.00 ➝ $40.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$333.79M	2.17	$1.39 per share	9.38	$7.06 per share	1.84
PNTG The Pennant Group	$695.24M	1.11	$0.89 per share	25.21	$9.08 per share	2.47
VMD Viemed Healthcare	$224.26M	1.15	$0.94 per share	6.88	$3.41 per share	1.91
VRDN Viridian Therapeutics	$300K	4,612.55	N/A	N/A	$6.09 per share	2.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	$52.55M	$1.15	11.09	N/A	N/A	19.79%	21.16%	14.25%	7/30/2025 (Estimated)
PNTG The Pennant Group	$22.56M	$0.76	29.42	25.52	1.98	3.40%	10.73%	4.00%	8/5/2025 (Estimated)
VMD Viemed Healthcare	$11.27M	$0.30	21.57	∞	N/A	5.28%	9.49%	7.14%	8/6/2025 (Estimated)
VRDN Viridian Therapeutics	-$269.95M	-$3.85	0.00	N/A	N/A	-102,092.39%	-70.61%	-44.67%	8/14/2025 (Estimated)

Latest VMD, VRDN, PNTG, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VRDN Viridian Therapeutics	-$1.01	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PNTG The Pennant Group	$0.26	N/A	N/A	N/A	$210.59 million	N/A
7/30/2025	Q2 2025	CDNA CareDx	$0.12	N/A	N/A	N/A	$90.72 million	N/A
5/7/2025	Q1 2025	VMD Viemed Healthcare	$0.06	$0.06	N/A	$0.06	$60.60 million	$59.10 million
5/6/2025	Q1 2025	VRDN Viridian Therapeutics	-$0.95	-$0.87	+$0.08	-$0.87	$0.16 million	$0.07 million
4/30/2025	Q1 2025	CDNA CareDx	$0.06	$0.09	+$0.03	-$0.19	$84.56 million	$84.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
VMD Viemed Healthcare	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.11	3.84
PNTG The Pennant Group	0.81	1.41	1.41
VMD Viemed Healthcare	0.03	1.38	1.26
VRDN Viridian Therapeutics	0.05	19.49	19.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
PNTG The Pennant Group	85.88%
VMD Viemed Healthcare	74.24%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDNA CareDx	4.40%
PNTG The Pennant Group	5.40%
VMD Viemed Healthcare	20.00%
VRDN Viridian Therapeutics	0.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	55.68 million	53.23 million	Optionable
PNTG The Pennant Group	7,000	34.47 million	32.61 million	Optionable
VMD Viemed Healthcare	1,179	39.52 million	31.62 million	Not Optionable
VRDN Viridian Therapeutics	50	81.59 million	81.06 million	Optionable

VMD, VRDN, PNTG, and CDNA Headlines

Recent News About These Companies

Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

July 19 at 3:33 AM | marketbeat.com

Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial

July 15, 2025 | msn.com

Rice Hall James & Associates LLC Acquires 309,518 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

July 14, 2025 | marketbeat.com

Viridian Therapeutics price target lowered to $38 from $41 at Evercore ISI

July 11, 2025 | msn.com

Viridian Therapeutics Sees Relative Strength Rating Improve To 79

July 10, 2025 | msn.com

Viridian Therapeutics (NASDAQ:VRDN) Trading Up 8.4% - Here's Why

July 9, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | finance.yahoo.com

Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year

June 15, 2025 | investing.com

Viridian Therapeutics: The Song Remains The Same

June 9, 2025 | seekingalpha.com

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025 | businesswire.com

Veligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye disease

May 22, 2025 | healio.comH

Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts

May 21, 2025 | investing.com

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

May 20, 2025 | ophthalmologytimes.comO

Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.15%

May 15, 2025 | aaii.comA

Veligrotug receives breakthrough therapy designation for thyroid eye disease

May 9, 2025 | healio.comH

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025 | finance.yahoo.com

Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats

May 6, 2025 | in.investing.com

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025 | finance.yahoo.com

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2025 | zacks.com

Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.71%

April 16, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD, VRDN, PNTG, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$13.02 +0.27 (+2.12%)

Closing price 04:00 PM Eastern

Extended Trading

$12.96 -0.05 (-0.42%)

As of 07:58 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

The Pennant Group NASDAQ:PNTG

$22.46 -0.78 (-3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$22.44 -0.02 (-0.07%)

As of 06:08 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Viemed Healthcare NASDAQ:VMD

$6.50 +0.03 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$6.50 +0.00 (+0.08%)

As of 04:02 PM Eastern

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Viridian Therapeutics NASDAQ:VRDN

$16.96 +0.17 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$16.98 +0.02 (+0.09%)

As of 04:26 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time